Recent Press Releases

The Greek company “ANTAEA Medical Services Ltd.” won the lawsuit against “ATLAS Medical Services Ltd.” and Özdemir Hiçdurmaz

The Greek company "ANTAEA Medical Services Ltd." won the lawsuit against "ATLAS Medical Services Ltd." and Özdemir Hiçdurmaz for unfair competition, in the Turkish...

Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome

BOSTON, Oct. 1, 2014 -- Zafgen, Inc. (ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic...

LSP RAISES EUR 80 MLN TO INVEST IN MEDICAL INNOVATIONS

LSP (Life Sciences Partners) today announced that it has raised EUR 80 mln (USD 100 mln) for its new fund LSP 5. This fund will continue LSP's proven and successful strategy of investing in...

Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance

Detailed Data Showing Andexanet Alfa Significantly Reversed Anticoagulation Activity of Factor Xa Inhibitor Eliquis to be Featured at American Heart Association's "Clinical Science: Special...

Enanta Regains Full Rights to NS5A Inhibitor EDP-239 for Hepatitis C Virus from Novartis

WATERTOWN, Mass., October 1, 2014 — Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the...

Enanta Regains Full Rights to NS5A Inhibitor EDP-239 for Hepatitis C Virus from Novartis

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc., (ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease...

Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate

CAMBRIDGE, Mass.--Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced favorable safety results from the single ascending dose portion of a...

Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study

Pfizer Inc. (PFE) and Kyowa Hakko Kirin (Tokyo:4151), announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566, an...

GSK commits further funding to advance bioelectronics research with creation of $5 million Innovation Challenge Fund

GSK today announced a $5 million Innovation Challenge Fund (ICF) to further encourage and advance collaborative research as part of its effort to develop bioelectronic medicines. The fund will...

Nimbus Discovery Appoints Donald Nicholson, Ph.D. as Chief Executive Officer

Nimbus Discovery Appoints Donald Nicholson, Ph.D. as Chief Executive Officer -- Critical hire at time of major transformation in the company's evolution – Cambridge, Mass. – September...

Johnson & Johnson Announces Agreement To Acquire Alios BioPharma

NEW BRUNSWICK, N.J., Sept. 30, 2014 -- Johnson & Johnson today announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused...

Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps

TARRYTOWN, N.Y. and PARIS, Sept. 30, 2014 -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of...

Mucosis Presents Infectious Diseases Vaccines Pipeline Update at SACHs Associates 14th Annual Biotech in Europe Forum

Fern Lazar/Danielle Lewis+1.212.867.1762orSue Charles/AUS: +61 (0) 466 924218Daniel Gooch/UK: +44 (0) 20 7866 7905

MacroGenics and Takeda Enter Second Strategic Alliance to Develop Multiple Additional DART Therapeutics

ROCKVILLE, Maryland and OSAKA, Japan - September 29, 2014 - MacroGenics, Inc.MGNX, +2.77% and Takeda Pharmaceutical Company Limited jointly announced today that they have entered into a collaboration...

BioMed Realty Trust Signs A New 12-Year Lease Establishing New Innovation And R&D Center In Kendall Square In Cambridge, Massachusetts

CAMBRIDGE, Mass., Sept. 29, 2014 -- BioMed Realty Trust, Inc. announced today the signing of a new lease for approximately 200,000 square feet for 12 years with Baxter Healthcare Corporation, a...

Catalyst Pharmaceuticals Announces Positive Top-Line Phase 3 Data From Pivotal Firdapse Clinical Trial in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)

Treatment with Firdapse achieved statistical significance for both co-primary clinical endpoints Catalyst expects to initiate rolling NDA submission in early-2015 Conference call tomorrow, September...

Biosimilars Set to Revolutionize Global Drug Development Industry with More Than 700 Therapies in Pipelines

PHILADEPHIA, Sept. 29, 2014 /PRNewswire/ -- The Intellectual Property and Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and...

CTI Clinical Trial and Consulting Services Opens San Francisco, CA Office

FOR IMMEDIATE RELEASE [Cincinnati, OH ~ September 29, 2014] CTI Clinical Trial and Consulting Services (CTI), a multinational, privately held, full-service contract research organization announces...

Kamada Announces Second Extension of Strategic Agreement with Baxter

Kamada Announces Second Extension of Strategic Agreement with Baxter Increases minimum Glassia sales through 2017 to a total of over $190 million since 2010 NESS ZIONA, Israel--(BUSINESS WIRE)--...

Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team

Atlas Venture Names Jason Rhodes, Veteran Investor and President and CFO of Epizyme, As Partner on Life Sciences Investing Team CAMBRIDGE, Mass., Sept. 29, 2014 /PRNewswire/ -- Atlas Venture, an...